Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

NCT04931862 is registered in ClinicalTrials.gov with Wave Life Sciences USA, Inc. as lead sponsor.

NCT NCT04931862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04931862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
Lead sponsor
Wave Life Sciences USA, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
June 28, 2021
Completion date
June 27, 2023
Enrollment
35 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

als, ftd